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Proprotein Convertase
Subtilisin/Kexin Type 9 as
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Influences on Cellular
Cholesterol
A Case for Resistin*
Sergio Fazio, MD, PHD, MacRae F. Linton, MD
Nashville, Tennessee
Circulating cholesterol represents a small fraction (less than
3%) of whole body cholesterol (1,2), and its concentration
depends on the balance between lipoprotein output (from
liver and intestine) and lipoprotein clearance (mostly by the
liver); both processes are regulated at the cellular level.
Cholesterol exerts all its functions within cells, serving as a
structural element of cellular membranes and a substrate for
the production of bioactive molecules such as bile acids,
steroids, sex hormones, and vitamin D. Thus, it should not
come as a surprise that the regulation of cholesterol fluxes in
the body is designed around the needs of individual cells,
with the extracellular compartment playing the role of
passive reservoir. Each cell is equipped with the machinery
to produce cholesterol in a highly synchronized fashion and
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to modulate the intake of plasma-derived cholesterol via
regulated expression of the low-density lipoprotein receptor
(LDLR). For many years, all the known components of the
cellular cholesterol regulation pathways were exclusively
intracellular (3). In case of cholesterol depletion, the sterol
regulatory element-binding proteins (SREBPs) activate a
transcriptional counter-response aimed at increasing syn-
thesis of cholesterol via up-regulation of 3-hydroxy-3-
methylglutaryl–coenzyme A reductase and at increasing
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in conditions of cholesterol surplus, the SREBP pathway is
inactive, and both cholesterol synthesis and LDLR expres-
sion are reduced. The discovery of proprotein convertase
subtilisin/kexin type 9 (PCSK9), a secretory enzyme that
post-transcriptionally regulates levels of LDLR by inducing
its degradation, has drastically changed our understanding
of the principles of cholesterol homeostasis (4,5). Although
synthesized under the regulation of SREBPs and therefore
under the control of cellular cholesterol changes, PCSK9 is
a protein that is secreted and transported in plasma, thus
acting in autocrine, paracrine, and endocrine modes to
regulate LDLR levels in ways that may override regulation
of cholesterol entry based on the needs of each specific cell
(6,7). Therefore, this protein represents the weakest link in
the cell-based regulation of cholesterol fluxes because it is
exposed to possible regulatory effects of other proteins that
may significantly influence its plasma and tissue distribu-
tion, its half-life, and its ability to bind to and degrade the
LDLR. This “physiological exposure” of the system that
regulates cellular cholesterol homeostasis may represent the
basis for moderate and severe forms of hypercholesterolemia
that are not attributable to genetic causes, a common
finding (from 17% to 38% of individuals studied) in cohorts
of subjects carrying a dyslipidemic phenotype clinically
compatible with familial hypercholesterolemia (8,9). Influ-
ences on intracellular cholesterol regulation seem justifiable
at the physiological level. For example, it has been proposed
that insulin up-regulates the expression of hepatic PCSK9
(10). This regulatory effect of the pancreas over intracellular
cholesterol homeostasis could serve the purpose of reducing
hepatic lipoprotein uptake after the absorption of a meal, in
line with the physiological principle of preferentially distrib-
uting chylomicrons to extrahepatic tissues. The effect of
insulin on PCSK9 is, however, mediated by SREBP mod-
ulation and thus part of an orchestrated choreography of
changes in cholesterol-regulating genes. Other influences
may be less ontologically justifiable, less physiologically
predictable, and less coordinately regulated.
In this issue of the Journal, Melone et al. (11) present
evidence that resistin, a small protein secreted by cells such
as macrophages in humans and adipocytes in rodents (12),
increases PCSK9 expression in liver cells and therefore
reduces LDLR levels on the cell membrane. Resistin levels
are increased in obesity and may contribute to the insulin
resistance and low level of inflammation seen in patients
with the metabolic syndrome (13,14). The novel mecha-
nism of PCSK9 up-regulation by resistin may contribute to
the dyslipidemia commonly observed in obesity, which is
often characterized by altered levels of all lipid parameters,
including low-density lipoprotein (LDL) (15,16). Indeed,
Melone et al. (11) go on to show that the plasma of obese
subjects, containing high levels of resistin, had a stronger
ability to reduce LDLR on liver cells compared with plasma
from lean subjects, containing lower amounts of resistin.
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antibodies against resistin. Interestingly, the regulation of
PCSK9 by resistin was only partially explained by transcrip-
tional influences. Although there was a definite, 3-fold
SREBP-dependent up-regulation of PCSK9, a silencing
experiment using small interfering ribonucleic acid against
the PCSK9 transcript also suggested significant post-
transcriptional regulation, possibly via stabilization of the
PCSK9 protein already produced. If these results are con-
firmed, the implications for our understanding of the
physiology of cholesterol homeostasis and for the develop-
ment of cholesterol therapeutics are very significant, possi-
bly revolutionary. If a regulator of intracellular cholesterol
fluxes is influenced post-transcriptionally by circulating
proteins unrelated to cholesterol metabolism, then it is
possible that the distribution of plasma cholesterol levels in
populations reflects, more or less prominently, mechanisms
independent from those regulated by established cholesterol
genes. Even more profoundly, these results suggest that the
tightly regulated machinery in charge of cellular cholesterol
homeostasis allows for cholesterol-independent influences
from the extracellular milieu to act on the LDLR, the main
port of entry into the hepatic cell for circulating cholesterol.
An extracellular signal to diminish LDLR levels would be
easily defused by the efficient and comprehensive cellular
counter-regulatory response, and thus not expected to in-
fluence vital cell functions. On the other hand, the reduced
cellular uptake of cholesterol would result in its accumula-
tion in the plasma compartment, where no counter-
regulatory mechanisms exist.
Even more interestingly, the authors show that not all of
the effect of resistin on LDLR was mediated by the
up-regulation or stabilization of PCSK9, because a lesser
but still significant reduction in LDLR was also seen in cells
that do not express PCSK9 (11). Although this may seem
confusing and at odds with the hypothesis put forward by
the authors (i.e., that resistin acts via PCSK9 to affect
LDLR), the result actually represents an intriguing addition
to the story line. Because resistin has structural similarity
with the cysteine-rich domain in the carboxyl-terminal
region of PCSK9 (17), it is easy to speculate that resistin
may also interact directly with the LDLR and, as with
PCSK9, induce its degradation. The similarity between the
2 proteins in a region such as the cysteine-rich domain,
prone to creation of intermolecular disulfide bonding, may
also cause resistin and PCSK9 to form aggregation com-
plexes, which may explain the stabilizing effect of resistin on
PCSK9 protein when the PCSK9 message is reduced by
small interfering ribonucleic acid treatment.
Finally, the influence of resistin on cellular cholesterol
homeostasis, either direct or mediated by PCSK9, may
explain the wide distribution of LDL-lowering responses to
statin therapy in patients. Variability of response to therapy
has been shown to be evident particularly in obese subjects
(18,19). It is possible that higher levels of plasma resistin in
obese individuals may reduce the LDL-lowering effect ofstatin by amplifying the up-regulation of PCSK9, already
known to be an unintended consequence of statin therapy
caused by the activation of SREBP (20,21). In the study of
Melone at al. (11), liver cells treated with lovastatin showed
the expected increase in LDLR, but the addition of resistin
increased PCSK9 levels and reduced the statin effect on
LDLR both by more than 50%. To make this story more
complex, statins are known to down-regulate synthesis of
resistin, thus reducing its plasma concentration (22,23).
Therefore, “resistance” to statin therapy may be caused not
only by an effect of resistin on PCSK9, possibly more
prominent in obese subjects, but also by an inability of the
statin to down-regulate resistin in the first place. The paper
by Melone et al. (11) opens a door into a new world where
the regulation of intracellular cholesterol is influenced by
circulating proteins apparently unrelated to cholesterol ho-
meostasis. Although direct inhibition of PCSK9 via anti-
body therapy is currently an active area of investigation
(24,25), future intervention may target this protein indi-
rectly via down-regulation or blockade of physiological
factors such as resistin.
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